Sabrina Serani

A phase 2 trial yielded encouraging results for pembrolizumab plus lenvatinib in uveal melanoma, showing promising progression-free survival rates.

XTR008 therapy shows significant benefits in treating GEP-NETs, enhancing survival rates and quality of life compared to octreotide LAR.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin.

FDA designates MNV-201 as an orphan drug for myelodysplastic syndrome, highlighting its innovative approach to mitochondrial dysfunction treatment.

Acalabrutinib shows high efficacy and safety for treating chronic lymphocytic leukemia in older, frail patients, improving frailty scores significantly.

Discover the most anticipated abstracts on gastrointestinal cancers at the 2025 ESMO Congress, featuring groundbreaking studies and innovative treatments.

Sonrotoclax receives FDA breakthrough designation, promising new hope for patients with relapsed mantle cell lymphoma after standard treatments fail.

A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.

The FDA fast-tracks WTX-124, a promising therapy for advanced melanoma, aiming to improve treatment options for patients with limited choices.

Long-term study reveals active surveillance is a safe management strategy for low-risk papillary thyroid cancer, especially in older patients.

A phase 1 study reveals promising safety and efficacy of NBTXR3 combined with radiotherapy and immunotherapy for resistant melanoma patients.

FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted delivery methods.

A phase 2 study reveals low-dose nivolumab and lenalidomide as a promising, safe, chemotherapy-free treatment for classical Hodgkin lymphoma.

CAR T-cell therapy for DLBCL shows promise in outpatient settings, reducing hospital stays and improving patient quality of life while managing toxicities effectively.

The FDA prioritizes Orca-T's review for treating hematologic malignancies, promising improved survival and reduced complications compared with traditional therapies.

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.

The FDA approves lurbinectedin and atezolizumab for first-line maintenance in extensive-stage small cell lung cancer, significantly enhancing survival rates.

FDA fast tracks ETX-636, a promising treatment for advanced breast cancer with PIK3CA mutations, aiming to improve patient outcomes.

FDA accepts T-DXd for neoadjuvant HER2-positive breast cancer treatment, promising improved outcomes and safety for high-risk patients.

Discover the most anticipated late-breaking abstracts in gastrointestinal cancers at ESMO 2025 and influence the conversation in oncology research.

Dr Sarah Premji discusses advancements in breast cancer treatment, emphasizing community trials, personalized therapies, and how to address unmet patient needs.

Umoja Biopharma's UB-VV111 receives FDA fast track designation, advancing CAR T cell therapy for relapsed/refractory B-cell malignancies.

Explore upcoming PDUFA action dates for innovative oncology treatments, including promising therapies for hard-to-treat cancers in late 2025.

A groundbreaking trial reveals trastuzumab deruxtecan significantly improves survival in high-risk HER2-positive breast cancer patients post-neoadjuvant therapy.

FDA approves imlunestrant for advanced breast cancer, enhancing treatment options for patients with ESR1 mutations through innovative genomic profiling.

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective heart rhythm monitoring.

The FDA approves imlunestrant, offering a new oral treatment option for advanced ER-positive breast cancer, enhancing patient outcomes and management.

New clinical data reveals stenoparib significantly extends survival in advanced platinum-resistant ovarian cancer, offering hope for patients with limited options.